-
8861“…The therapy for chronic hepatitis C (CH–C) started with interferon (IFN) monotherapy in the early 1990s and this therapy was considered effective in about 10% of cases. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8862“…Several scenarios can be proposed: 1) the appearance of a new infection (AIDS or SARS); 2) the appearance of a known infection where it did not exist previously (West Nile virus infection in the USA); 3) an infection that existed but that was not diagnosed or could not be linked precisely to a particular infectious agent (hepatitis C before the discovery of the hepatitis C virus; 4) a known infection that increases its usual incidence (outbreaks…); 5) infectious diseases for which current conditions may facilitate transmission (decrease of immunization coverage...). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8863por Pereira, Rita de Cassia Ribeiro, Heming, Carolina Augusta Modena, Tejo, Thiago Ramos, de Oliveira, Thais Cristina Lima, da Silva, Rita do Socorro Uchoa, Parente, Daniella Braz“…MATERIALS AND METHODS: We evaluated 38 patients with hepatitis B, coinfected or not with hepatitis D, or with chronic hepatitis C, all of whom underwent contrast-enhanced multiphase dynamic computed tomography. …”
Publicado 2020
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8864por Doosti-Irani, Amin, Mokhaeri, Hamid, Chegini Sharafi, Ali, Aghasadeghi, Mohammad Reza, Hajimiragha, Morteza, Saki, Mohammad, Kayedi, Mohammad Hassan, Mostafavi, Ehsan“…Conclusions: According to this study, prevalence of HIV and hepatitis C among homeless people was considerable. …”
Publicado 2017
Enlace del recurso
Online Artículo Texto -
8865por Iradukunda, Patrick Gad, Habyarimana, Thierry, Niyonzima, Francois Niyongabo, Uwitonze, Ange-Yvette, Mpunga, Tharcisse“…Blood samples were collected and hepatitis B surface antigen (HBsAg) and an antibody against hepatitis C (Anti-HCV) were detected using an Enzyme-Linked Immuno-Sorbent Assay (ELISA). …”
Publicado 2020
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8866por Naguib, Mary, Helwa, Mohamed M, Soliman, Mohammed M, Abdel-Samiee, Mohamed, Eljaky, Ashraf M, Hammam, Osama, Zaghla, Hassan, Abdelsameea, Eman“…SECTION TITLE: Several major risk factors for hepatocellular carcinoma (HCC) have been identified, including chronic infection of hepatitis B virus (HBV) and hepatitis C virus (HCV). Nevertheless, only a fraction of infected patients develops HCC during their lifetime suggesting that genetic factors might modulate HCC development. …”
Publicado 2020
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8867“…We discuss this clinical research gap within an historical context of viral treatment as prevention for HIV and hepatitis C, and comment on the challenges and opportunities for clinical research of candidate therapeutics for early COVID-19 disease.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8868por Bekki, Shigemune, Hashimoto, Satoru, Yamasaki, Kazumi, Komori, Atsumasa, Abiru, Seigo, Nagaoka, Shinya, Saeki, Akira, Suehiro, Tomoyuki, Kugiyama, Yuki, Beppu, Asami, Kuroki, Tamotsu, Nakamura, Minoru, Ito, Masahiro, Yatsuhashi, Hiroshi“…BACKGROUND: We examined serum kynurenine levels in patients with chronic hepatitis C virus infection, and the relationship between serum kynurenine and prognosis in patients with hepatocellular carcinoma (HCC) and chronic hepatitis C. …”
Publicado 2020
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8869por Kneller, Daniel W., Galanie, Stephanie, Phillips, Gwyndalyn, O'Neill, Hugh M., Coates, Leighton, Kovalevsky, Andrey“…The enzyme active-site cavity reveals a high degree of malleability, allowing aldehyde leupeptin and hepatitis C clinical protease inhibitors (telaprevir, narlaprevir, and boceprevir) to bind and inhibit SARS-CoV-2 3CL M(pro). …”
Publicado 2020
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8870por Ianevski, Aleksandr, Yao, Rouan, Biza, Svetlana, Zusinaite, Eva, Männik, Andres, Kivi, Gaily, Planken, Anu, Kurg, Kristiina, Tombak, Eva-Maria, Ustav, Mart, Shtaida, Nastassia, Kulesskiy, Evgeny, Jo, Eunji, Yang, Jaewon, Lysvand, Hilde, Løseth, Kirsti, Oksenych, Valentyn, Aas, Per Arne, Tenson, Tanel, Vitkauskienė, Astra, Windisch, Marc P., Fenstad, Mona Høysæter, Nordbø, Svein Arne, Ustav, Mart, Bjørås, Magnar, Kainov, Denis E.“…Here, we identify new synergistic combinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), echovirus 1 (EV1), hepatitis C virus (HCV) and human immunodeficiency virus 1 (HIV-1) in vitro. …”
Publicado 2020
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8871por Ju, Jingyue, Li, Xiaoxu, Kumar, Shiv, Jockusch, Steffen, Chien, Minchen, Tao, Chuanjuan, Morozova, Irina, Kalachikov, Sergey, Kirchdoerfer, Robert N., Russo, James J.“…Based on our analysis of hepatitis C virus and coronavirus replication, and the molecular structures and activities of viral inhibitors, we previously reasoned that the FDA‐approved hepatitis C drug EPCLUSA (Sofosbuvir/Velpatasvir) should inhibit coronaviruses, including SARS‐CoV‐2. …”
Publicado 2020
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8872por Chen, Hongyi, Zhang, Zhicheng, Wang, Li, Huang, Zhihua, Gong, Fanghua, Li, Xiaodong, Chen, Yahong, Wu, Jinzi J.“…Danoprevir boosted by ritonavir (Ganovo) is a potent hepatitis C virus (HCV) protease (NS3/4A) inhibitor, which was approved and marketed in China since 2018 to treat chronic hepatitis C patients. …”
Publicado 2020
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8873por Pacella, Ilenia, Spinelli, Francesca Romana, Severa, Martina, Timperi, Eleonora, Tucci, Gloria, Zagaglioni, Marta, Ceccarelli, Fulvia, Rizzo, Fabiana, Coccia, Eliana M, Patel, Roosheel S, Martin‐Fernandez, Marta, Bogunovic, Dusan, Conti, Fabrizio, Barnaba, Vincenzo, Piconese, Silvia“…In vivo, in patients with chronic hepatitis C, 2 days after starting pegIFN/ribavirin therapy, a stronger ISG15 inducibility correlates with a milder Treg depletion. …”
Publicado 2020
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8874por Bertino, Gaetano, Ragusa, Rosalia, Corsaro, Liberato Simone, Frazzetto, Evelise, Messina, Vincenzo, Inguscio, Lucio, Lai, Carlo, Maglia, Marilena, Nunnari, Andrea, Caponnetto, Pasquale“…HCV (Hepatitis C Virus) decreases Health-Related Quality of Life with detriments to physical, mental and social health domains. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8875“…The limit of detection of 9.1 ng/μL of the hepatitis C virus core antigen, a biomarker for hepatitis C, was achieved using this multicolorimetric ELISA platform. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8876por Valiakou, Vaia, Eliadis, Petros, Karamichali, Eirini, Tsitsilonis, Ourania, Koskinas, John, Georgopoulou, Urania, Foka, Pelagia“…Host lipid metabolism reprogramming is essential for hepatitis C virus (HCV) infection and progression to severe liver disease. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8877por Dhiman, Radha K., Grover, Gagandeep S., Premkumar, Madhumita, Roy, Akash, Taneja, Sunil, Duseja, Ajay, Arora, Sanjeev“…BACKGROUND: The prevalence of chronic hepatitis C (CHC) in People Who Inject Drugs (PWID) is 8-10% as compared to 3·6% in the general population in Punjab, India. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8878por González Grande, Rocío, Santaella Leiva, Inmaculada, López Ortega, Susana, Jiménez Pérez, Miguel“…Understanding of the mechanisms of transmission, the pathogenesis, the presence of vaccinations and the development over recent years of new highly-efficient, potent drugs have meant that we are now faced with a new scenario in the management of viral hepatitis, particularly hepatitis B virus and hepatitis C virus. The spectacular advances in hepatitis C virus treatment have led the World Health Organization to propose the objective of its eradication by 2030. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8879Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures“…HCC occurs in several pre-existing conditions, including hepatitis C, hepatitis B virus, and non-alcoholic cirrhosis. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8880“…Still, their successful use against RNA viruses is very recent, despite RNA viruses comprising some of the most damaging human pathogens (e.g., Coronaviruses, Influenza viruses, or Flaviviridae such as dengue, Zika and hepatitis C viruses). The breakthrough came in 2013–2014, when the nucleoside analog Sofosbuvir became one of the cornerstones of current curative treatments for hepatitis C virus (HCV). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto